Teplizumab-mzwv: Perspective on clinical practice and use at a single institution
SMART-MD Journal of Precision Medicine · 2025
DOI: 10.69734/59hkbn82 ↗Kurz gefasst
Fachartikel in der Zeitschrift SMART-MD Journal of Precision Medicine, 2025. Verfasst von Jamie L. Felton und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of insulin-producing beta cells in the pancreas. Early intervention with teplizumab-mzwv (brand name Tzield) can be considered to delay the need for insulin therapy for patients with Stage 2 T1D ≥8 years of age. Eligibility requires the presence of at least two islet autoantibodies in addition to evidence of dysglycemia, but without meeting Stage 3 T1D glycemic criteria. Clinical practice and experience with this treatment is expanding; however, approval, access, administration, and subsequent monitoring practices remain variable in general practice. Here we present a brief discussion regarding our experience with teplizumab-mzwv at the Riley Hospital for Children at Indiana University Health.
Zitieren
APA
Felton, J. L., Tuttle, A., & Sims, E. K. (2025). Teplizumab-mzwv: Perspective on clinical practice and use at a single institution. SMART-MD Journal of Precision Medicine. https://doi.org/10.69734/59hkbn82
Vancouver
Felton JL, Tuttle A, Sims EK. Teplizumab-mzwv: Perspective on clinical practice and use at a single institution. SMART-MD Journal of Precision Medicine. 2025. doi:10.69734/59hkbn82
BibTeX
@article{Felton2025,
author = {Felton, Jamie L. and Tuttle, Alex and Sims, Emily K.},
title = {Teplizumab-mzwv: Perspective on clinical practice and use at a single institution},
journal = {SMART-MD Journal of Precision Medicine},
year = {2025},
doi = {10.69734/59hkbn82}
}
EUVIMED